相关实验视频

Updated: Jul 5, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

基于同步化疗或放射治疗的治疗模式的有效性在IIB期宫状细胞癌患者中

Xin-Bin Pan¹, Yan Lu², You-Sheng Wei²

¹Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China.

|January 18, 2024

概括

辅助化疗 (AC) 并没有改善IIB期宫平状细胞癌 (CSCC) 患者的生存结果,这些患者同时接受化疗放射治疗 (CCRT). 需要进一步的研究来优化CSCC患者的治疗策略.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
妇科瘤学妇科瘤学

背景情况:

宫平细胞癌 (CSCC) 阶段IIB是一个局部发达的疾病.
同时化疗放射治疗 (CCRT) 是一种标准治疗,但最佳辅助策略仍在研究中.
了解治疗模式及其对生存的影响对于改善患者的治疗结果至关重要.

研究的目的:

评估不同治疗模式的生存影响,包括CCRT在IIB阶段的CSCC.
为了比较单独使用CCRT和CCRT与新辅助化疗 (NACT) 和/或辅助化疗 (AC) 结合的结果.

主要方法:

从2012年6月到2019年6月,对232名IIB阶段的CSCC患者进行了回顾性分析,这些患者接受了CCRT治疗.
根据接受的治疗来对患者进行分类:单独使用CCRT,NACT+CCRT,CCRT+AC,NACT+CCRT+AC.
使用Kaplan-Meier方法和倾向性得分匹配的生存分析来比较治疗组.

主要成果:

与单独使用CCRT相比,CCRT + AC的整体存活率 (OS) 和局部无转移存活率 (LRFS) 类似,但远程无转移存活率 (DMFS) 更差.
在倾向得分匹配后,CCRT+AC显示了与单独的CCRT可比的OS,LRFS和DMFS.
在这个患者队列中,在AC添加到CCRT时没有观察到显著的生存益处.

结论:

辅助化疗似乎没有改善CCRT接受的IIB期CSCC患者的生存率.
将AC添加到CCRT并没有在OS,LRFS或DMFS方面提供显著的生存优势.
目前的研究结果表明,AC可能对这一患者群体没有好处,因此需要进一步研究最佳治疗强化策略.

关键词:

在CSCC中,CSCC是最重要的.宫支状细胞癌是宫支状细胞癌.化疗化疗是一种化学疗法.放射疗法是一种放射治疗.第二阶段IIB阶段

更多相关视频

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...